| Literature DB >> 28717159 |
Lorena Ruiz1,2, Francesca Bottacini1, Christine J Boinett3, Amy K Cain3, Mary O'Connell-Motherway1, Trevor D Lawley3, Douwe van Sinderen4.
Abstract
Bifidobacteria are common gut commensals with purported health-promoting effects. This has encouraged scientific research into bifidobacteria, though recalcitrance to genetic manipulation and scarcity of molecular tools has hampered our knowledge on the precise molecular determinants of their health-promoting attributes and gut adaptation. To overcome this problem and facilitate functional genomic analyses in bifidobacteria, we created a large Tn5 transposon mutant library of the commensal Bifidobacterium breve UCC2003 that was further characterized by means of a Transposon Directed Insertion Sequencing (TraDIS) approach. Statistical analysis of transposon insertion distribution revealed a set of 453 genes that are essential for or markedly contribute to growth of this strain under laboratory conditions. These essential genes encode functions involved in the so-called bifid-shunt, most enzymes related to nucleotide biosynthesis and a range of housekeeping functions. Comparison to the Bifidobacterium and B. breve core genomes highlights a high degree of conservation of essential genes at the species and genus level, while comparison to essential gene datasets from other gut bacteria identified essential genes that appear specific to bifidobacteria. This work establishes a useful molecular tool for scientific discovery of bifidobacteria and identifies targets for further studies aimed at characterizing essential functions not previously examined in bifidobacteria.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28717159 PMCID: PMC5514069 DOI: 10.1038/s41598-017-05795-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Genome-wide distribution of transposon insertions in B. breve UCC2003. Circular plot showing gene content, insertion distribution and gene comparison to Bifidobacterium and B. breve core genomes. Circular tracks are numbered from 1 (outer track) to 7 (inner track). Track 1 represents transposon insertion densities; track 2 indicates forward and reverse genes predicted in B. breve UCC2003 genome; track 3 indicates core B. breve genes; track 4 indicates B. breve core genes present in single copy; track 5 represents B. breve single copy core genes present in Bifidobacterium genus core genes; track 6 represents TraDIS predicted essential genes and track 7 represents GC bias, khaki indicates values > 1; purple < 1.
Figure 2Reconstruction of essential metabolic pathways and functions, based on TraDIS-predicted essential genes in B. breve UCC2003. Gene names or locus tags are represented in red and metabolic intermediates in grey. Dashed arrows summarize multiple reactions. Panels A and B represent the essential central carbohydrate utilization pathways, bifid shunt and pentose phosphate pathway, respectively. Panel C represents essential steps within amino acid metabolism and biosynthesis pathways. Panel D highlights essential steps mapped onto nucleotide metabolic pathways.
COG and KEGG classification of B. breve essential genes.
| COG Family | Pathway (KEGG) | Genes | %* |
|---|---|---|---|
| Amino acid transport and metabolism | Alanine aspartate glutamate | 2 | 0.5% |
| Amino acid related functions | 3 | 0.8% | |
| Glycine serine threonine | 1 | 0.3% | |
| Selenocompounds | 1 | 0.3% | |
| Carbohydrate transport and metabolism | Transporters | 4 | 1.0% |
| Amino sugar metabolism | 1 | 0.3% | |
| Bifid shunt | 3 | 0.8% | |
| Carbohydrate related functions | 5 | 1.3% | |
| Carbohydrate transport and metabolism | 2 | 0.5% | |
| Glycolysis/gluconeogenesis | 2 | 0.5% | |
| Glycosyl hydrolases | 2 | 0.5% | |
| Pentose phosphate | 7 | 1.7% | |
| Cell cycle control, cell division, chromosome partitioning | Cell cycle control, cell division, chromosome partitioning | 6 | 1.5% |
| Cell wall/membrane/envelope biogenesis | Alanine aspartate glutamate | 1 | 0.3% |
| Amino sugar metabolism | 1 | 0.3% | |
| Capsule biosynthesis | 6 | 1.5% | |
| Cell wall associated functions | 8 | 2.0% | |
| D-alanine | 2 | 0.5% | |
| Peptidoglycan biosynthesis | 9 | 2.3% | |
| Coenzyme transport and metabolism | Coenzyme related functions | 4 | 1.0% |
| Cysteine methionine | 1 | 0.3% | |
| Folate | 4 | 1.0% | |
| Nicotinate nicotinamide metabolism | 3 | 0.8% | |
| Panthotenate coA | 1 | 0.3% | |
| Riboflavin utilization (energy metabolism) | 1 | 0.3% | |
| Thiamine | 1 | 0.3% | |
| Defence mechanism | Transporters | 3 | 0.8% |
| Defence mechanism | 4 | 1.0% | |
| DNA, replication, recombination and repair | DNA related functions | 3 | 0.8% |
| Recombination | 4 | 1.0% | |
| Repair | 5 | 1.3% | |
| Replication | 15 | 3.8% | |
| Energy production and conversion | Citrate cycle | 2 | 0.5% |
| Energy production conversion related functions | 13 | 3.3% | |
| Pyruvate metabolism | 1 | 0.3% | |
| Inorganic ion transport and metabolism | Transporters | 12 | 3.0% |
| Inositol phosphate | 1 | 0.3% | |
| Intracellular trafficking, secretion, and vesicular transport | Secretion | 1 | 0.3% |
| Secretion (sec pathway) | 7 | 1.8% | |
| Lipid transport and metabolism | Fatty acids biosynthesis | 3 | 0.8% |
| Lipids metabolism | 5 | 1.3% | |
| Panthotenate coA | 1 | 0.3% | |
| Terpenoid | 7 | 1.8% | |
| Nucleotide transport and metabolism | Cysteine methionine | 1 | 0.3% |
| Nucleotide related functions | 1 | 0.3% | |
| Purine metabolism | 9 | 2.3% | |
| Pyrimidine metabolism | 11 | 2.8% | |
| Nucleotide transport and metabolism | 2 | 0.5% | |
| Posttranslational modification, protein turnover, chaperones | Posttranslational modification, protein turnover, chaperones | 12 | 3.0% |
| RNA processing and modification | RNA processing and modification | 3 | 0.8% |
| Signal transduction mechanisms | Signal transduction mechanisms | 3 | 0.8% |
| Signal transduction related functions | 6 | 1.5% | |
| Transcription | RNA polymerase | 4 | 1.0% |
| Transcription | 1 | 0.3% | |
| Transcriptional regulator | 10 | 2.5% | |
| Translation, ribosomal structure and biogenesis | Ribosome | 52 | 13.0% |
| Translation | 18 | 4.5% | |
| tRNA processing and modification | 2 | 0.5% | |
| tRNA synthetase | 22 | 5.5% | |
| tRNA-dihydrouridine synthase | 4 | 1.0% | |
| General function prediction only | General function prediction only | 15 | 3.8% |
| Unassigned function | Unassigned function | 56 | 14.0% |
| TOTAL | 400 | 100.0% |
*Percentage of the protein encoding predicted essential genes from B. breve UCC2003, mapped into each COG and KEGG functional category.
Figure 3(a) Venn Diagram representing the overlap between the essential genes determined by TraDIS analysis for B. breve UCC2003, the Bifidobacterium and B. breve core genomes, as well as B. breve core genes present in single copy. (b) Heatmap representing in colour gradient the frequency of COG categories across all the different type of gene families resulting from comparative analysis of B. breve UCC2003 total gene content and TraDIS predicted essential genes, against the available Bifidobacterium genomes.
Figure 4(a) Venn Diagram representing the overlap of essential genes determined by transposon sequencing in B. breve UCC2003, Bacteroides fragilis 638 R and Bacteroides thetaiotaomicron VPI-5482. (b) Distribution per COG functional classification of essential genes in the three compared taxa.
Oligonucleotides and plasmids used in this work.
| Name | Sequence | Reference |
|---|---|---|
|
| ||
| pMOD2 | Source of Tn | Epicentre Biotechnology |
| pMOD2-tetT7 | tetR pMOD2 derivative, containing outwards facing T7 promoters at both transposon ends | This work |
| Fw-Tet-pMOD2T7 | CGCTAG | This work |
| Rev-Tet-pMOD2T7 | CGCTAG | This work |
| pMOD < MCS > Fw | ATTCAGGCTGCGCAACTGT | Epicentre Biotechnology |
| pMOD < MCS > Rev | GTCAGTGAGCGAGGAAGCGGAAG | Epicentre Biotechnology |
|
| ||
| 5′ PCR enrichment primer sequence | AATGATACGGCGACCACCGAGATCTACACAATTCGAGCCAATATGCGAGAACACCCG | This work |
| 3′ PCR enrichment primer sequence | AATGATACGGCGACCACCGAGATCTACACATGCAAGCTTGCCAACGACTACGCACTAGC | This work |
| 5′ Sequencing primer sequence | ACCCGAGAAAATTCATCGATGATGGTTGAGATGTGTA | This work |
| 3′ Sequencing primer sequence | ACCCGAGAAAATTCATCGATGATGGTTGAGATGTGTA | This work |
aRestriction sites are underlined.